• H Melliez, D Levybruhl, P Y Boelle, B Dervaux, S Baron, and Y Yazdanpanah.
• Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, France. hugues.melliez@orange.fr <hugues.melliez@orange.fr>
• Vaccine. 2008 Jan 30; 26 (5): 706-15.

ObjectivesTo assess the effectiveness and cost-effectiveness of routine childhood vaccination by new vaccines against rotavirus in France.MethodsWe constructed a Markov decision tree to compare two alternatives: "no vaccination" and "vaccination". A hypothetical birth cohort of 750,000 children was followed until 3 years of age. First, the disease burden without vaccine was estimated using data from French databases and medical literature. Incidence rates in unvaccinated children were modelled as a function of age and seasons. Next, using data from the medical literature, the vaccine's protective effect on rotavirus diarrhoea was considered.ResultsA routine universal rotavirus immunization programme was estimated capable of annually avoiding 89,000 cases of diarrhoea, 10,500 hospitalizations, and 8 deaths. At a vaccination cost of euro 150/course, assuming 75% vaccine coverage, the programme would cost euro 95 million and involve a net loss of euro 68 million to the health care system. The vaccination programme would cost euro 298,000/year of life saved, and euro 138,000/QALY saved. Key variables affecting the results were disease incidence, mortality rates and vaccine price.ConclusionIn France, childhood rotavirus vaccination with new anti-rotavirus vaccines would reduce the morbidity burden of rotavirus infection, but would not be cost-effective unless the price of vaccine decreased considerably.

22 keywords...

hide…